R&D Trends: Asthma - Extensive Investment in Novel Targets

Description: From preclinical to preregistration, 139 products are in development for asthma. These are analyzed by phase and formulation, and clinical trial trends are discussed. The future of treatment is assessed, as are innovative early-stage approaches.

Datamonitor identified 139 products in development for asthma in 2012. In the near term Datamonitor expects that there will be little change in treatment regimens but strong innovation is seen in earlier stages and Datamonitor expects that novel targeted therapies could make their way through the pipeline, aimed at niche patient groups.

Scope

- Support R&D decision-making by understanding what is driving development in the pipeline.
- Analyze clinical trial design to understand how the desired indication impacts endpoint choice.
- Assess novel early-stage approaches and the future of treatment in asthma, with insight from key opinion leaders.
- Benchmark pipeline candidates using the ideal target product profile identified by Datamonitor.

Highlights

- Datamonitor identified 139 products in development for asthma. Earlier stages in particular show significant diversity with numerous targets under investigation. Many of these will fail to progress through the pipeline, but those that do could offer a novel treatment option. These will be particularly important for patients with refractory asthma.

- Lung function measures have been used extensively in clinical trials for asthma. However, clinical trials for biologics in asthma should have a different focus. AstraZeneca’s current Phase IIb trial of tralokinumab has a primary endpoint of asthma exacerbations over 52 weeks.

- Severe asthma remains a significant cause of mortality and morbidity and a portion of patients remain inadequately controlled despite combination treatment. Few innovations have been seen recently in asthma, despite significant research and numerous proposed targets. Still, strong investments continue, and novel therapies could reach the market.

Reasons to Purchase

- How does the late-stage pipeline differ from early stages and what is driving investment in asthma R&D?
- How does clinical trial design differ between drug classes and what lessons have been learned from trials of biologics?
- Which early-stage approaches are the most promising and how will they change future treatment?
- What would it take for a pipeline candidate to see success in the highly penetrated asthma market?

Contents:

OVERVIEW
- Catalyst
- Summary

EXECUTIVE SUMMARY
- Strategic scoping and focus
- Datamonitor key findings
- Related reports

CLINICAL PIPELINE OVERVIEW
- Wide variation of targets in the pipeline
- Numerous oral products in development
- Xolair mechanism of action
- Development compounds recently discontinued

TARGET PRODUCT PROFILE
- Advair (fluticasone/salmeterol; GlaxoSmithKline)
- Xolair (omalizumab; Genentech/Novartis)
- Target product profile versus current level of attainment

CLINICAL TRIAL DESIGN IN ASTHMA
- Clinical trial design
  - Active comparators
  - Trial duration
  - Patient selection
  - Clinical trial endpoint measures
- Typical Phase III development program in asthma
- Future developments in clinical trial design
- LABA safety studies required in the US

INNOVATIVE EARLY-STAGE APPROACHES
- CRTH2 antagonists represent a large proportion of drugs in early-stage development
- Biologics are making their way through the pipeline

THE FUTURE OF TREATMENT IN ASTHMA
- Simplified treatment expected in the medium and long term
- Novel targeted therapies for niche patient groups

BIBLIOGRAPHY
- Journal papers
- Websites

APPENDIX
- Contributing experts
- Conferences attended
- Report methodology

TABLES
Table: Products in clinical development for asthma, 2012
Table: Products in preclinical development for asthma, 2012
Table: Recently discontinued pipeline candidates for asthma, 2012
Table: Advair (fluticasone/salmeterol; GlaxoSmithKline) - drug profile, 2012
Table: Xolair (omalizumab; Genentech/Novartis) - drug profile, 2012
Table: Advair and Xolair versus the minimum acceptable product profile and target product profile, April 2012
Table: Phase III trial designs in asthma, 2012
Table: Most promising innovative therapeutic approaches in asthma, 2012
Table: CRTH2 antagonists in development for asthma, 2012
Table: Biologics in development for asthma, 2012

FIGURES
Figure: Pipeline candidates for asthma, by phase of development, 2012
Figure: Clinical pipeline for asthma, by mechanism of action and phase, 2012
Figure: Clinical pipeline for asthma, by formulation and phase, 2012
Figure: Xolair (omalizumab; Genentech/Novartis) mechanism of action
Figure: Biologics in development for asthma, by mechanism of action, 2012
Figure: Future developments in the treatment of asthma, 2012

Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: R&D Trends: Asthma - Extensive Investment in Novel Targets
Web Address: http://www.researchandmarkets.com/reports/2159001/
Office Code: SCD2AZ9T

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Electronic (PDF) -</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Single User:</td>
<td>USD 3800</td>
</tr>
<tr>
<td></td>
<td>Electronic (PDF) -</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Enterprisewide:</td>
<td>USD 9500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr] [Mrs] [Dr] [Miss] [Ms] [Prof]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World